Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by PoorOpinionon Dec 03, 2018 12:52pm

109 Views

Post# 29055031

RE:RE:RE:Corner Turning

Also only about the same as Sept, so the difficulty would seem to be trying to calc growth where some of the increases in sales for Nov were already accounted for in Octs shipment.

One glimmer of hope is the market seems to be responding to this metric now, it feels underwhelming and the market responded appropriately.

juniper88 wrote: I found a link:

https://translate.google.ca/translate?hl=en&sl=zh-TW&u=https://www.cnyes.com/twstock/bincome/4147.htm&prev=search

So, the revenue was 39007 thousand TWD, not 3900 million TWD. If you take out the one time account item from October, the November revenue is pretty much the same as October.

Hod did you determne that means 380 patients in November?